TR199900289T2 - Kontrollü alfuzosin hidroklorür salma özelligine sahip tablet. - Google Patents

Kontrollü alfuzosin hidroklorür salma özelligine sahip tablet.

Info

Publication number
TR199900289T2
TR199900289T2 TR1999/00289T TR9900289T TR199900289T2 TR 199900289 T2 TR199900289 T2 TR 199900289T2 TR 1999/00289 T TR1999/00289 T TR 1999/00289T TR 9900289 T TR9900289 T TR 9900289T TR 199900289 T2 TR199900289 T2 TR 199900289T2
Authority
TR
Turkey
Prior art keywords
layer
hydrophilic polymers
release
tablet
alfuzosin hydrochloride
Prior art date
Application number
TR1999/00289T
Other languages
English (en)
Inventor
Maggi Lauretta
Conte Ubaldo
Grenier Pascal
Vergnault Guy
Dufour Alain
Xavier Jarreau Fran�Ois
Rauch-Desanti Clemence
Original Assignee
Synthelabo
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26232935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR199900289(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR9610551A external-priority patent/FR2752737B1/fr
Application filed by Synthelabo, Jagotec Ag filed Critical Synthelabo
Publication of TR199900289T2 publication Critical patent/TR199900289T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Bulus; a)katman agirliginin %5-90'ini, tercihen %10-85'ini teskil eden hidrofilik polimerlerden olusan bir karisimin veya bir granülün sikistirilmasi ile üretilen, sulandirilmis biyolojik sivilarla temas ettiginde dikkat çekecek kadar ve hizla kabarma özelligine sahip olan bir birinci katmandan(1); b)ilaca uygun sikistirilabilirlik özelliklerini vermek ve belirli bir zaman periyodu içerisinde alfuzosin hidroklorürün salinimina imkan vermek üzere hidrofilik polimerlerle ve diger yardimci maddelerle formüle edilen, içerisinde alfuzosin hidroklorür tasinan, birinci katmana bitisik olan bir ikinci katmandan(2); c)ve aktif maddenin geçisine karsi yüksek ölçüde geçirmez olan, özellikle peltelesen ve/veya kabaran ve daha sonra istege bagli olarak ayrisabilen hidrofilik polimerlerden olusan ve katman 2'den alfuzosin hidroklorür salinimini modifike eden bir bariyer fonksiyonuna sahip olan, sikistirmayla elde edilen ve katman 2'ye uygulanan, istege bagli olan bir üçüncü katmandan...DEVAMI VAR^
TR1999/00289T 1996-08-29 1997-08-22 Kontrollü alfuzosin hidroklorür salma özelligine sahip tablet. TR199900289T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9610551A FR2752737B1 (fr) 1996-08-29 1996-08-29 Comprime a liberation controlee de chlorhydrate d'alfuzosine
FR9704386 1997-04-10

Publications (1)

Publication Number Publication Date
TR199900289T2 true TR199900289T2 (tr) 2000-12-21

Family

ID=26232935

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/00289T TR199900289T2 (tr) 1996-08-29 1997-08-22 Kontrollü alfuzosin hidroklorür salma özelligine sahip tablet.

Country Status (37)

Country Link
US (1) US6149940A (tr)
EP (1) EP0938318B1 (tr)
JP (1) JP3797388B2 (tr)
KR (1) KR100364328B1 (tr)
CN (2) CN100335057C (tr)
AP (1) AP1107A (tr)
AR (1) AR009312A1 (tr)
AT (1) ATE200864T1 (tr)
AU (1) AU724490B2 (tr)
BG (1) BG63768B1 (tr)
BR (1) BR9713237B1 (tr)
CA (1) CA2264250C (tr)
CO (1) CO4920217A1 (tr)
CY (1) CY2284B1 (tr)
CZ (1) CZ295066B6 (tr)
DE (1) DE69704712T2 (tr)
DK (1) DK0938318T3 (tr)
EE (1) EE03855B1 (tr)
ES (1) ES2159400T3 (tr)
GR (1) GR3036291T3 (tr)
HK (1) HK1020875A1 (tr)
HU (1) HU228007B1 (tr)
IL (1) IL128146A (tr)
IS (1) IS2091B (tr)
MX (1) MXPA99001958A (tr)
NO (1) NO326206B1 (tr)
NZ (1) NZ334018A (tr)
OA (1) OA10983A (tr)
PL (1) PL191546B1 (tr)
PT (1) PT938318E (tr)
RU (1) RU2183459C2 (tr)
SI (1) SI0938318T1 (tr)
SK (1) SK284388B6 (tr)
TR (1) TR199900289T2 (tr)
TW (1) TW522023B (tr)
UA (1) UA69374C2 (tr)
WO (1) WO1998008515A1 (tr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720471B1 (en) 1998-04-28 2004-04-13 The Procter & Gamble Company Absorbent articles having reduced rewet with distribution materials positioned underneath storage material
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
FR2784583B1 (fr) * 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
EP1251832B1 (en) 2000-02-04 2006-09-27 Depomed, Inc. Shell-and-core dosage form approaching zero-order drug release
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
FR2820318B1 (fr) * 2001-02-08 2005-12-23 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant un principe actif et comprime obtenu
FR2820319B3 (fr) * 2001-02-08 2003-12-05 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu
US6777000B2 (en) 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7163696B2 (en) * 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
US7309444B2 (en) * 2002-08-29 2007-12-18 Stellar Technology Company Layered tablet water treatment compositions and method of use
US6852238B2 (en) * 2002-08-29 2005-02-08 Steller Technology Company Layered tablet water treatment compositions and method of use
AU2003270778B2 (en) 2002-09-20 2009-10-08 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
AU2003278407A1 (en) * 2002-10-22 2004-05-13 Ranbaxy Laboratories Limited Sustained release compositions containing alfuzosin
RU2377976C2 (ru) * 2004-07-29 2010-01-10 Санофи-Авентис ФАРМАЦЕВТИЧЕСКАЯ МНОГОСЛОЙНАЯ ТАБЛЕТКА ДЛЯ КОНТРОЛИРУЕМОГО ВЫСВОБОЖДЕНИЯ АКТИВНЫХ ИНГРЕДИЕНТОВ С РАСТВОРИМОСТЬЮ, В ВЫСОКОЙ СТЕПЕНИ ЗАВИСЯЩЕЙ ОТ pH
FR2874325B1 (fr) * 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
US20060062845A1 (en) * 2004-09-17 2006-03-23 Cimex Pharma Ag Alfuzosin tablets and synthesis
US20060062846A1 (en) * 2004-09-17 2006-03-23 Cimex Pharma Ag Alfuzosin tablets and synthesis
ITMI20050391A1 (it) * 2005-03-11 2006-09-12 Ph & T S P A Formulazioni a rilascio controllato di alfuzosin
US9198608B2 (en) 2005-04-28 2015-12-01 Proteus Digital Health, Inc. Communication system incorporated in a container
US8912908B2 (en) 2005-04-28 2014-12-16 Proteus Digital Health, Inc. Communication system with remote activation
US8802183B2 (en) 2005-04-28 2014-08-12 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
WO2006116718A2 (en) 2005-04-28 2006-11-02 Proteus Biomedical, Inc. Pharma-informatics system
US8836513B2 (en) 2006-04-28 2014-09-16 Proteus Digital Health, Inc. Communication system incorporated in an ingestible product
CN101184780B (zh) 2005-05-05 2012-10-03 森馨香料公司 β-葡聚糖和甘露聚糖的制备
US20090238776A1 (en) * 2005-11-09 2009-09-24 Arif Ali Baig Oral Care Compositions and Methods
US7834066B2 (en) * 2005-11-09 2010-11-16 The Procter & Gamble Company Denture adhesive articles
US20070129460A1 (en) * 2005-11-09 2007-06-07 Jayanth Rajaiah Denture adhesive articles
US20070185233A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive articles
US20070185232A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive articles
US20090239972A1 (en) * 2005-11-09 2009-09-24 Jayanth Rajaiah Denture Adhesive Compositions and Methods
US20070185237A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive articles
US20070185236A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive compositions
US20070185235A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive compositions
EP1976488A4 (en) * 2006-01-12 2010-02-10 Wockhardt Ltd ALFUZOSIN PROLONGED RELEASE PREPARATIONS
CN105468895A (zh) 2006-05-02 2016-04-06 普罗透斯数字保健公司 患者定制的治疗方案
PT2034975E (pt) 2006-06-19 2012-06-25 Alpharma Pharmaceuticals Llc Composições farmacêuticas
US20080003286A1 (en) * 2006-06-29 2008-01-03 Sathya Narayana Vemula Sustained delivery alfuzosin compositions
EP2067475A4 (en) * 2006-09-26 2010-12-15 Astellas Pharma Inc PREPARATION FOR TACROLIMUS MAINTAINED RELEASE
US20080095844A1 (en) * 2006-10-23 2008-04-24 Rajhans Sujay Kamalakar Sustained release pharmaceutical compositions of alfuzosin and process for preparation thereof
SG175681A1 (en) 2006-10-25 2011-11-28 Proteus Biomedical Inc Controlled activation ingestible identifier
EP2069004A4 (en) 2006-11-20 2014-07-09 Proteus Digital Health Inc PERSONAL HEALTH SIGNAL RECEIVERS WITH ACTIVE SIGNAL PROCESSING
US20080138412A1 (en) * 2006-12-06 2008-06-12 Fu-Yung Lin Sustained release alfuzosin hydrochl formulation and method for their production
US20080160081A1 (en) * 2006-12-11 2008-07-03 Mutual Pharmaceutical Company, Inc. Alfuzosin formulations, methods of making, and methods of use
US20100092556A1 (en) * 2006-12-11 2010-04-15 Kristin Arnold Alfuzosin formulations, methods of making, and methods of use
WO2008084698A1 (ja) 2006-12-28 2008-07-17 Astellas Pharma Inc. タクロリムス徐放性医薬組成物
ES2930588T3 (es) 2007-02-01 2022-12-19 Otsuka Pharma Co Ltd Sistemas de marcador de eventos ingeribles
CA3000257C (en) 2007-02-14 2020-04-28 Proteus Digital Health, Inc. In-body power source having high surface area electrode
WO2008102235A1 (en) * 2007-02-20 2008-08-28 Aurobindo Pharma Limited Controlled release formulations of alfuzosin
US9270025B2 (en) 2007-03-09 2016-02-23 Proteus Digital Health, Inc. In-body device having deployable antenna
US8932221B2 (en) 2007-03-09 2015-01-13 Proteus Digital Health, Inc. In-body device having a multi-directional transmitter
US8115618B2 (en) 2007-05-24 2012-02-14 Proteus Biomedical, Inc. RFID antenna for in-body device
FI2192946T3 (fi) 2007-09-25 2022-11-30 Elimistön sisäinen laite, jossa on virtuaalinen dipolisignaalinvahvistus
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
DK2268261T3 (en) 2008-03-05 2017-08-28 Proteus Digital Health Inc Edible event markers with multi-mode communications and systems as well as methods for using them
SG195535A1 (en) 2008-07-08 2013-12-30 Proteus Digital Health Inc Ingestible event marker data framework
CN104382598A (zh) 2008-08-13 2015-03-04 普罗透斯数字保健公司 一种产生识别器的方法
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
AU2010203737B2 (en) 2009-01-06 2016-09-15 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical dosages delivery system
JP2012514799A (ja) 2009-01-06 2012-06-28 プロテウス バイオメディカル インコーポレイテッド 摂取に関連するバイオフィードバックおよび個別薬物療法の方法およびシステム
US20100183717A1 (en) * 2009-01-16 2010-07-22 Kristin Arnold Controlled-release formulations
GB2480965B (en) 2009-03-25 2014-10-08 Proteus Digital Health Inc Probablistic pharmacokinetic and pharmacodynamic modeling
SG175388A1 (en) 2009-04-28 2011-12-29 Proteus Biomedical Inc Highly reliable ingestible event markers and methods for using the same
EP2432458A4 (en) 2009-05-12 2014-02-12 Proteus Digital Health Inc ACCEPTABLE EVENT MARKER WITH SUGAR COMPONENT
TWI517050B (zh) 2009-11-04 2016-01-11 普羅托斯數位健康公司 供應鏈管理之系統
JP5730915B2 (ja) 2010-03-10 2015-06-10 ザ プロクター アンド ギャンブルカンパニー 義歯接着剤組成物
TR201802207T4 (tr) 2010-03-29 2018-03-21 Astellas Pharma Inc Kontrollü Salımlı Farmasötik Bileşim.
JP5905872B2 (ja) * 2010-04-07 2016-04-20 ルピン・リミテッド タペンタドールの制御放出医薬組成物
AU2011237612B2 (en) 2010-04-07 2016-05-12 Otsuka Pharmaceutical Co., Ltd. Miniature ingestible device
TWI557672B (zh) 2010-05-19 2016-11-11 波提亞斯數位康健公司 用於從製造商跟蹤藥物直到患者之電腦系統及電腦實施之方法、用於確認將藥物給予患者的設備及方法、患者介面裝置
EP2642983A4 (en) 2010-11-22 2014-03-12 Proteus Digital Health Inc DEVICE INGREABLE WITH PHARMACEUTICAL PRODUCT
CN102475690B (zh) * 2010-11-30 2016-06-01 安国药品株式会社 内含盐酸阿夫唑嗪的缓释片剂
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
KR101898964B1 (ko) 2011-07-21 2018-09-14 프로테우스 디지털 헬스, 인코포레이티드 모바일 통신 장치, 시스템, 및 방법
US9235683B2 (en) 2011-11-09 2016-01-12 Proteus Digital Health, Inc. Apparatus, system, and method for managing adherence to a regimen
KR20150038038A (ko) 2012-07-23 2015-04-08 프로테우스 디지털 헬스, 인코포레이티드 섭취 가능한 부품을 포함하는 섭취 가능한 이벤트 마커를 제조하기 위한 기술
JP5869736B2 (ja) 2012-10-18 2016-02-24 プロテウス デジタル ヘルス， インコーポレイテッド 通信デバイス用の電源において電力消失およびブロードキャスト電力を適応的に最適化するための装置、システム、および方法
JP2016508529A (ja) * 2013-01-29 2016-03-22 プロテウス デジタル ヘルス， インコーポレイテッド 高度に膨張可能なポリマーフィルムおよびこれを含む組成物
US10175376B2 (en) 2013-03-15 2019-01-08 Proteus Digital Health, Inc. Metal detector apparatus, system, and method
JP6511439B2 (ja) 2013-06-04 2019-05-15 プロテウス デジタル ヘルス， インコーポレイテッド データ収集および転帰の査定のためのシステム、装置、および方法
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
WO2017078557A1 (ru) * 2015-11-05 2017-05-11 Анатолий Викторович ЗАЗУЛЯ Изготовление таблетки с механизмом повышения терапевтической эффективности лекарственного средства нанодозой аналога
KR20210018961A (ko) 2016-07-22 2021-02-18 프로테우스 디지털 헬스, 인코포레이티드 섭취 가능한 이벤트 마커의 전자기 감지 및 검출
CA3041041A1 (en) 2016-10-26 2018-05-03 Proteus Digital Health, Inc. Methods for manufacturing capsules with ingestible event markers
CN114209668B (zh) * 2022-01-13 2023-01-31 山东新时代药业有限公司 一种盐酸阿夫唑嗪缓释制剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2582513B1 (fr) * 1985-05-28 1988-08-05 Synthelabo Compositions pharmaceutiques contenant de l'alfuzosine
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
GB9311191D0 (en) * 1993-05-29 1993-07-14 Danbiosyst Uk Controlled release drug formulation
FR2717388B1 (fr) * 1994-03-21 1996-11-22 Synthelabo Formes galéniques à libération prolongée du chlorhydrate d'alfuzosine.

Also Published As

Publication number Publication date
DE69704712T2 (de) 2001-11-29
DK0938318T3 (da) 2001-08-20
TW522023B (en) 2003-03-01
NO990944D0 (no) 1999-02-26
ATE200864T1 (de) 2001-05-15
IS2091B (is) 2006-03-15
EP0938318B1 (fr) 2001-05-02
JP3797388B2 (ja) 2006-07-19
CA2264250A1 (en) 1998-03-05
WO1998008515A1 (fr) 1998-03-05
HUP9903428A3 (en) 2000-04-28
CZ295066B6 (cs) 2005-05-18
BG103138A (en) 1999-09-30
BR9713237B1 (pt) 2009-01-13
HUP9903428A2 (hu) 2000-02-28
IL128146A0 (en) 1999-11-30
AP9901470A0 (en) 1999-03-31
IL128146A (en) 2001-01-11
GR3036291T3 (en) 2001-10-31
SK27099A3 (en) 1999-12-10
AP1107A (en) 2002-09-20
OA10983A (fr) 2003-03-04
IS4964A (is) 1999-01-29
RU2183459C2 (ru) 2002-06-20
BG63768B1 (bg) 2002-12-29
US6149940A (en) 2000-11-21
EP0938318A1 (fr) 1999-09-01
CY2284B1 (en) 2003-07-04
AU724490B2 (en) 2000-09-21
MXPA99001958A (es) 2005-09-08
CN100335057C (zh) 2007-09-05
NO326206B1 (no) 2008-10-20
AU4020197A (en) 1998-03-19
KR20000035929A (ko) 2000-06-26
HK1020875A1 (en) 2000-05-26
BR9713237A (pt) 2000-04-04
PL331862A1 (en) 1999-08-16
HU228007B1 (en) 2012-08-28
EE9900090A (et) 1999-10-15
ES2159400T3 (es) 2001-10-01
CN1228700A (zh) 1999-09-15
CO4920217A1 (es) 2000-05-29
CZ65599A3 (cs) 1999-06-16
NO990944L (no) 1999-04-27
PL191546B1 (pl) 2006-06-30
CN1543954A (zh) 2004-11-10
KR100364328B1 (ko) 2002-12-26
PT938318E (pt) 2001-10-30
UA69374C2 (uk) 2004-09-15
SI0938318T1 (en) 2001-12-31
AR009312A1 (es) 2000-04-12
JP2000514462A (ja) 2000-10-31
CA2264250C (en) 2005-07-05
NZ334018A (en) 1999-06-29
SK284388B6 (sk) 2005-02-04
CN1155382C (zh) 2004-06-30
DE69704712D1 (de) 2001-06-07
EE03855B1 (et) 2002-10-15

Similar Documents

Publication Publication Date Title
TR199900289T2 (tr) Kontrollü alfuzosin hidroklorür salma özelligine sahip tablet.
TR199700614T1 (tr) Sulu akiskanlarin tutulmasi için kullanima yönelik yüksek iç fazli emülsiyonlardan yapilan emici köpükler.
Steers et al. An investigation of dose titration with darifenacin, an M3‐selective receptor antagonist
HUP9800796A2 (hu) Menstruációs párnák abszorbens tagjaiként használható, nagy belső fázisú emulziókból készült habok
DK390584D0 (da) Tvaerbundne, poroese polymerer til brug ved reguleret laegemiddelafgivlse
DE122007000022I1 (de) Pharmazeutische Zusammensetzungen, welche ausgewählte Lanthancarbonathydrate enthalten
Bharucha et al. Taking a lesson from microbial diarrheagenesis in the management of chronic constipation
KR20000005337A (ko) 가교결합된 아밀로즈 및 하이드록시프로필메틸셀룰로즈계담체를 함유하는 서방성 약제학적 정제
RU99105730A (ru) Таблетка с регулируемым высвобождением алфузозина гидрохлорида
TR199701083T1 (tr) Transdermal uygulama için farmasötik kompozisyon.
TR200001942T2 (tr) Opioid agonist/antagonist kombinasyonlar
KR880009639A (ko) 서방성 매트릭스 제형
US20050003725A1 (en) Absorbent article
Spencer et al. Inhibition of Neisseria gonorrhoeae genital tract infection by leading-candidate topical microbicides in a mouse model
Wedi Urticaria
KR950005314A (ko) 제산제 조성물 및 약제 조성물
BR9908746A (pt) Estrutura absorvente e artigos absorventes descartáveis que incluem a mesma
RU95107880A (ru) Твердая фармацевтическая форма
KR20110115063A (ko) 접착성 함수 겔시트
AU2002256333B2 (en) A release pharmaceutical construct for gastric retention
Vogelnest et al. The suitability of medetomidine sedation for intradermal skin testing in dogs
WO2001064201A3 (en) Restricting reinstatement of drug use
AU2002256333A1 (en) A release pharmaceutical construct for gastric retention
Mijinyawa et al. Choice of antihypertensive medications among physicians and its impact on blood pressure control among Nigerians living with hypertension
BRPI0406580A (pt) Uso de carbamato de (s)-n-etil-n-metil-3-[1-(dimetilamino)etil]-fenil, uso de um ou mais ingredientes ativos e medicamento para a profilaxia de envenenamento por inibidores de colinesterase